TriSalus Life Sciences forecasts 2026 revenue between $54M and $57M as company executes commercial expansion strategy. The biotech firm is positioning itself for multiyear growth following deliberate organizational realignment in Q1. However, the TriNav Advance product clearance has experienced delays, running approximately five months past initial timeline goals. CEO Mary Szela characterized the quarter as a deliberate build year focused on capturing anticipated growth opportunities. The revenue guidance reflects management confidence in upcoming clinical developments and commercial execution despite regulatory setbacks. Investors should monitor product launch timelines and commercial traction closely as the company invests heavily in sales infrastructure to support projected revenue growth trajectory.
Post from MarketNews_en
Log in to interact with content.